injectables

Reduce Pain During Procedures

Reduce Pain During Procedures

Pain—and the fear of pain—is one of the key factors that discourages patients from undergoing injectable and laser treatments. But there are several steps physicians can take to reduce pain during noninvasive cosmetic treatments. Speaking at the American Society for Laser Medicine & Surgery conference in Phoenix, Kenneth Arndt, MD, of Skincare Physicians in Chestnut Hill, Massachusetts, shared the following strategies to make patients more comfortable during treatment.

Savings Vs. Safety

The FDA is cracking down on physicians who purchase injectables from non-U.S. suppliers.
The FDA is cracking down on physicians who purchase injectables from non-U.S. su

Attendees at the January American Academy of Cosmetic Surgery Annual Scientific Meeting in Las Vegas were buzzing about the cautionary tale related by Andrew S. Ittleman, Esq. in his presentation “Doctors’ Use of Foreign-Sourced Injectables.” Ittleman, a founder and partner with the law firm Fuerst Ittleman David & Joseph in Miami, Florida, specializes in complex disputes with the United States government, including the Food and Drug Administration.

Neurotoxins May Aid in Dermal Remodeling

Intradermal injections of botulinum toxin type A (BoNT) may offer some dermal remodeling effects, according to researchers at Chungnam National University’s Department of Plastic and Reconstructive Surgery in South Korea. S.H. Oh, et al, measured procollagen type I carboxy-terminal peptide (PIP) in dermal fibroblasts grown in the presence of BoNT, using an enzyme-linked immunosorbent assay. Collagen production was monitored using Western blotting. The researchers also measured matrix metalloproteinase using gelatin zymography.

Pliaglis Receives FDA Approval

The United States Food and Drug Administration (www.fda.gov) has approved a supplemental New Drug Application (sNDA) for topical local anesthetic Pliaglis (lidocaine/tetracaine) 7%/7% Cream. Galderma Laboratories (www. galderma.com), a global pharmaceutical company that specialize in dermatology, will distribute Pliaglis, having licensed worldwide marketing rights from Nuvo Research Inc.